Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.
Wen-Zhao ZhongQun WangWei-Min MaoSong-Tao XuLin WuYu-Cheng WeiYong-Yu LiuChun ChenYing ChengRong YinFan YangSheng-Xiang RenXiao-Fei LiJian LiCheng HuangZhi-Dong LiuShun XuKe-Neng ChenShi-Dong XuLun-Xu LiuPing YuBu-Hai WangHai-Tao MaJin-Ji YangHong-Hong YanXue-Ning YangSi-Yang LiuQing ZhouYi-Long WuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2020)
Adjuvant therapy with gefitinib in patients with early-stage NSCLC and EGFR mutation demonstrated improved DFS over standard of care chemotherapy. Although this DFS advantage did not translate to a significant OS difference, OS with adjuvant gefitinib was one of the longest observed in this patient group compared with historic data.
Keyphrases
- small cell lung cancer
- phase iii
- early stage
- epidermal growth factor receptor
- open label
- clinical trial
- advanced non small cell lung cancer
- phase ii
- brain metastases
- double blind
- healthcare
- sentinel lymph node
- phase ii study
- placebo controlled
- palliative care
- tyrosine kinase
- electronic health record
- case report
- study protocol
- big data
- locally advanced
- lymph node
- randomized controlled trial
- free survival
- combination therapy
- wild type
- squamous cell carcinoma
- health insurance